GABA

Recent articles

Research image of excitatory synapses in the prefrontal cortex.

Synaptic anomalies in autistic people support imbalance hypothesis

Increased excitatory and decreased inhibitory synapses in the prefrontal cortex of autistic people suggest broader impacts on brain function and connectivity.

By Giorgia Guglielmi
27 June 2024 | 4 min read
Image of the dorsal raphe area of the brain.

Neurotransmitter switch-up helps fan extreme stress into full-blown fear

The flip occurs when certain neurons in the dorsal raphe start to express the chemical GABA instead of glutamate, a new study shows.

By Claudia López Lloreda
9 April 2024 | 5 min read
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

Looking at eye tracking’s potential for clinical trials

This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.

By Calli McMurray
28 September 2023 | 6 min read
Photograph of white pills and blister pack on blue pastel colored background.

Trials of arbaclofen for autism yield mixed results

Autistic children taking the drug showed improvements in some behaviors but not in their social skills.

By Giorgia Guglielmi
5 May 2023 | 5 min read
Research image of cultured neurons.

Cannabis compound rebalances signaling to quell seizures in mice

Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.

By Peter Hess
22 March 2023 | 5 min listen

Single gene insufficient to account for dup15q, Angelman traits

UBE3A, a key gene associated with both autism-linked conditions, can explain most — but not all — of the syndromes’ atypical neuronal properties.

By Angie Voyles Askham
21 March 2023 | 6 min read
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Null and Noteworthy: Busting biomarkers; going after GABA; reproducibility illusion

In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.

By Laura Dattaro
16 February 2023 | 4 min read
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses

Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.

By Peter Hess
25 January 2023 | 6 min read
Single astrocyte on black background.

Mouse studies cast astrocytes as stars of sensory perception

Data from two separate research teams suggest the cells are key to sensory hypersensitivity in fragile X syndrome.

By Sarah DeWeerdt
13 November 2022 | 4 min read
Laura Cancedda in Iama's lab.

Building a better drug

Iama Therapeutics is hoping a new class of molecule will prove successful against an old target in autism.

By Alla Katsnelson
6 October 2022 | 12 min read

Explore more from The Transmitter

Coins flow from a spigot.

Newly awarded NIH grants for neuroscience lag 77 percent behind previous nine-year average

Since President Donald Trump took office on 20 January, the National Institute of Neurological Disease and Stroke and the National Institute of Mental Health have awarded one quarter as many new grants as during the same two-month period, on average, since 2016.

By Natalia Mesa
4 April 2025 | 5 min read
Raphael Yuste leaning on a bench in his lab. A red filter colors the scene.

Releasing the Hydra with Rafael Yuste

Losing HHMI Investigator status caused Yuste to study neural networks in a new way.

By Brady Huggett, Shaena Montanari
4 April 2025 | 10 min read
Glitchy image of a stamp.

Coding error caused layoffs at National Institute of Neurological Disorders and Stroke this week, source says

Thirty employees—including 11 lab heads—at the institute should “immediately return to work,” according to an email the institute’s Office of Human Resources sent to top administration at the institute Wednesday evening.

By Sydney Wyatt
3 April 2025 | 3 min read